NL-OMON21967招募中不适用
Identification of biological effects of bevacizumab in surgically resectable malignant melamoma.
MCG0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
/A
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1. Surgically resectable melanoma, stage III or IV;
- •2. WHO performance status 0-2;
排除标准
- •1. Prior chemotherapy or biological therapy for metastatic disease;
- •2. Prior radiotherapy on the involved area;
研究者
相似试验
尚未招募
2 期
Identification of biological effects of bevacizumab in surgically resectable melanoma tumors.melanoma cancer10040900skin cancerNL-OMON30987niversitair Medisch Centrum Groningen10
尚未招募
不适用
Phase 2 trial of utility and safety for bevacizumab in combination with adjuvant chemotherapy in cervical cancerCervical cancerJPRN-UMIN000026986Osaka medical college50
进行中（未招募）
1 期
The effect of bevacizumab treatment on reading ability in age related macular degeneration - Reading after bevacizumab treatment in AMDAge related macular degeneration of the eye, wet formMedDRA version: 12.1 Level: LLT Classification code 10064930 Term: Age-related macular degenerationEUCTR2010-024001-12-FITYKS50
Unknown
不适用
Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant ChemotherapyBevacizumabNeoadjuvant ChemotherapyMolecular Targeted TherapyBreast CancerNCT01652560LiNanlin,Ph.D, Chief Physician,Clinical Professor50
已完成
不适用
Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian CancerOvarian CancerNCT03367182Yonsei University50